Erick DeVinney to Chief Innovation OfficerMr. DeVinney joinedAxogen in April of 2007 as Director of Clinical Research. During his tenure, he has held positions of progressive responsibility in Clinical Research, Research and Development, Product Development, Medical Education, and Medical Affairs.Mr. DeVinney has more than 16 years of experience driving innovation in peripheral nerve injury diagnosis and repair, including clinical and regulatory development strategies, portfolio development, and scientific thought leadership. He has a diverse background, including academic research and the development of tissue technologies, medical devices, pharmaceuticals, and biologics.Mr. DeVinney has been involved in research at theVirginia Commonwealth University Medical College of Virginia Hospitals ,University of Utrecht ,National Clinical Research ,PRA International , and Angiotech. He has been involved in the successful submission of eight IDE or NDA applications, as well as numerous 510(k)s.Mr. DeVinney also serves as a Board Member for theGlobal Nerve Foundation . He has a B.S. degree in Chemistry fromVirginia Commonwealth University .
Ivica Ducic , M.D., Ph.D., to Chief Medical OfficerDr. Ducic joinedAxogen as Medical Director inJanuary 2017 . He is a board-certified plastic surgeon, with additional training and expertise in peripheral nerve surgery. He received his medical degree in 1991 from theUniversity of Zagreb School of Medicine (Croatia ,Europe ), and a Ph.D. degree in 1995 in neuroscience. Upon completing plastic surgery training atGeorgetown University Hospital in 2002, he entered a one-year peripheral nerve surgery fellowship. He then joined the full-time faculty practice atGeorgetown University Hospital Department of Plastic Surgery inAugust 2003 , where he served as a professor of plastic surgery and neurosurgery. In 2014,Dr. Ducic established his own practice, theWashington Nerve Institute inMcLean, Virginia . Among his many accomplishments,Dr. Ducic is the Past-President of theAmerican Society for Peripheral Nerve , has served on many committees, published more than 100 peer-reviewed papers, authored 17 book chapters, and has been a prolific invited educator both nationally and internationally on the diagnosis and treatment of peripheral nerve injury. During his past seven years atAxogen ,Dr. Ducic has been an instrumental leader in the development of new technologies, applicable surgical techniques, surgeon education, as well as providing strategic guidance for the core company mission – improving the quality of life of patients with nerve injuries.
Stacy Arnold to Vice President ofProduct Development and Clinical Research Ms. Arnold has served as Vice President of Clinical Research forAxogen sinceJune 2019 . She initially joinedAxogen inApril 2018 as Vice President of Program Management. She has been leading the research, development, and execution of clinical strategies to strengthen and advance the body of evidence for new technologies and clinical applications to restore nerve function and quality of life to patients with peripheral nerve injuries.Ms. Arnold previously served as Senior Director of R&D and Program Management at Artivion (formerly CryoLife), driving global innovation and new product development of medical devices, biologics, and tissue technologies, while leading successful program management processes and business strategies to drive growth and deliver shareholder value.Ms. Arnold serves as a Board Member on Mercer University’sNational Engineering Advisory Board . She has an M.S. in Engineering from theUniversity of Toledo and a B.S. in Biomedical Engineering fromMercer University . She also holds a global Project Management Professional Certification from theProject Management Institute .
In addition, the Company is announcing the departure of
“We want to thank Angelo for his contributions in new programs that led to innovations like the launch of Axoguard HA+ Nerve ProtectorTM and the upcoming launch of Avive+ Soft Tissue MatrixTM and we are pleased to announce the internal promotions of these leaders in our research and development team,” said
About
Axogen’s product portfolio includes Avance® nerve graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include the statement about the upcoming launch of Avive+ Soft Tissue Matrix, the departure of
For more information, visit www.axogeninc.com.
Contact:
htamayo@axogeninc.com
Source:
2024 GlobeNewswire, Inc., source